A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review”

Daniel E. Hilleman; Barbara S. Wiggins; Michael B. Bottorff

doi:10.1007/s12325-020-01420-z

A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review”

Daniel E. Hilleman, Barbara S. Wiggins, Michael B. Bottorff

Department of Pharmacy Practice

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	4046-4048
Number of pages	3
Journal	Advances in Therapy
Volume	37
Issue number	9
DOIs	https://doi.org/10.1007/s12325-020-01420-z
State	Published - Sep 1 2020

All Science Journal Classification (ASJC) codes

Pharmacology (medical)

Access to Document

10.1007/s12325-020-01420-z

Cite this

@article{20a3657621a14fb686de609806986657,

title = "A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review”",

author = "Hilleman, {Daniel E.} and Wiggins, {Barbara S.} and Bottorff, {Michael B.}",

note = "Funding Information: No Rapid Service Fee was received by the journal for the publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Editorial support for this letter was provided by Rohan Shah, PhD, of Peloton Advantage, an OPEN Health company, and funded by Amarin Pharma, Inc. The statements and opinions in this letter are those of the authors and not any other individual or entity. Daniel E. Hilleman has served on the speakers bureau for Amgen and Amarin and as a consultant for Heron Therapeutics. Barbara S. Wiggins has nothing to disclose. Michael B. Bottorff has served on the speakers bureau for Pfizer and BMS and as a consultant for Medisync. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Funding Information: Editorial support for this letter was provided by Rohan Shah, PhD, of Peloton Advantage, an OPEN Health company, and funded by Amarin Pharma, Inc. The statements and opinions in this letter are those of the authors and not any other individual or entity. ",

year = "2020",

month = sep,

day = "1",

doi = "10.1007/s12325-020-01420-z",

language = "English (US)",

volume = "37",

pages = "4046--4048",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Health Communications Inc.",

number = "9",

}

TY - JOUR

T1 - A Response to

T2 - Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review”

AU - Hilleman, Daniel E.

AU - Wiggins, Barbara S.

AU - Bottorff, Michael B.

N1 - Funding Information: No Rapid Service Fee was received by the journal for the publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Editorial support for this letter was provided by Rohan Shah, PhD, of Peloton Advantage, an OPEN Health company, and funded by Amarin Pharma, Inc. The statements and opinions in this letter are those of the authors and not any other individual or entity. Daniel E. Hilleman has served on the speakers bureau for Amgen and Amarin and as a consultant for Heron Therapeutics. Barbara S. Wiggins has nothing to disclose. Michael B. Bottorff has served on the speakers bureau for Pfizer and BMS and as a consultant for Medisync. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Funding Information: Editorial support for this letter was provided by Rohan Shah, PhD, of Peloton Advantage, an OPEN Health company, and funded by Amarin Pharma, Inc. The statements and opinions in this letter are those of the authors and not any other individual or entity.

PY - 2020/9/1

Y1 - 2020/9/1

UR - http://www.scopus.com/inward/record.url?scp=85087729019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087729019&partnerID=8YFLogxK

U2 - 10.1007/s12325-020-01420-z

DO - 10.1007/s12325-020-01420-z

M3 - Letter

C2 - 32647913

AN - SCOPUS:85087729019

SN - 0741-238X

VL - 37

SP - 4046

EP - 4048

JO - Advances in Therapy

JF - Advances in Therapy

IS - 9

ER -

A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review”

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this